Hetrombopag for low platelets during AML chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests hetrombopag to treat chemotherapy-related low platelet counts in adults with acute myeloid leukemia (AML) in remission. It aims to help keep platelets up so you can safely continue chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70
- You have confirmed AML that is in complete remission (and your platelets are at least 100)
- You finished initial (induction) treatment and have had no more than one round of strong “consolidation” chemotherapy, and you plan to continue chemotherapy
- You are able to do chemotherapy for at least 2 more cycles and expect to live at least 3 months
- Your general health is not too limited (ECOG 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This trial tests a drug called hetrombopag to see if it can prevent low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. It may help you avoid treatment delays or dose reductions.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.